blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2464666

EP2464666 - COMBINATION OF A HUMAN INTERLEUKIN-6 ANTAGONIST AND A HUMAN INTERLEUKIN-6 RECEPTOR ANTAGONIST IN THERAPY OF TUMOUR DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.01.2019
Database last updated on 26.06.2024
FormerThe patent has been granted
Status updated on  16.02.2018
FormerGrant of patent is intended
Status updated on  04.10.2017
FormerExamination is in progress
Status updated on  03.02.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Kovacs-Benke, Eva
Rheinparkstr. 5/12
4127 Birsfelden / CH
[2012/25]
Inventor(s)01 / see applicant
...
 [2012/25]
Representative(s)(deleted)
[2012/25]
Application number, filing date10746994.214.07.2010
[2018/12]
WO2010CH00183
Priority number, dateCH2009000110815.07.2009         Original published format: CH 11082009
[2012/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011006273
Date:20.01.2011
Language:EN
[2011/03]
Type: A1 Application with search report 
No.:EP2464666
Date:20.06.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 20.01.2011 takes the place of the publication of the European patent application.
[2012/25]
Type: B1 Patent specification 
No.:EP2464666
Date:21.03.2018
Language:EN
[2018/12]
Search report(s)International search report - published on:EP20.01.2011
ClassificationIPC:C07K16/24, C07K16/28, A61P35/00
[2012/25]
CPC:
C07K16/248 (EP); A61P35/00 (EP); C07K16/2866 (EP);
A61K2039/507 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/25]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:KOMBINATION AUS ANTAGONISTEN DES MENSCHLISCHEN INTERLEUKIN-6- UND ANTAGONISTEN DES MENSCHLISCHEN INTERLEUKIN-6-REZEPTORS ZUR BEHANDLUNG VON KREBS[2016/38]
English:COMBINATION OF A HUMAN INTERLEUKIN-6 ANTAGONIST AND A HUMAN INTERLEUKIN-6 RECEPTOR ANTAGONIST IN THERAPY OF TUMOUR DISEASES[2012/25]
French:COMBINAISON D'UN ANTAGONISTE DE L'INTERLEUKIN 6 HUMAINE ET D'UNANTAGONISTE DU RÉCEPTEUR HUMAIN DE L'INTERLEUKIN 6 POUR LE TRAITEMENT DES MALADIES TUMORALES[2016/26]
Former [2012/25]KOMBINATION AUS EINEM HUMANEN INTERLEUKIN-6 ANTAGONIST UND EINEM HUMANEN INTERLEUKIN-6-REZEPTORANTAGONIST BEI DER BEHANDLUNG VON TUMORERKRANKUNGEN
Former [2012/25]COMBINAISON D'UN ANTAGONISTE DE L'INTERLEUKINE-6 HUMAINE ET D'UN ANTAGONISTE DU RÉCEPTEUR DE L'INTERLEUKINE-6 HUMAINE DANS UNE THÉRAPIE CONTRE DES MALADIES TUMORALES
Entry into regional phase10.02.2012National basic fee paid 
10.02.2012Designation fee(s) paid 
10.02.2012Examination fee paid 
Examination procedure16.02.2012Examination requested  [2012/25]
08.03.2012Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time
21.11.2012Amendment by applicant (claims and/or description)
16.07.2013Despatch of a communication from the examining division (Time limit: M06)
23.01.2014Reply to a communication from the examining division
04.08.2014Despatch of a communication from the examining division (Time limit: M06)
02.02.2015Reply to a communication from the examining division
25.09.2015Despatch of a communication from the examining division (Time limit: M06)
15.02.2016Reply to a communication from the examining division
24.01.2017Despatch of a communication from the examining division (Time limit: M04)
01.03.2017Reply to a communication from the examining division
05.10.2017Communication of intention to grant the patent
06.02.2018Fee for grant paid
06.02.2018Fee for publishing/printing paid
08.02.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.07.2013
Opposition(s)02.01.2019No opposition filed within time limit [2019/09]
Request for further processing for:04.05.2012Request for further processing filed
04.05.2012Full payment received (date of receipt of payment)
Request granted
23.05.2012Decision despatched
Fees paidRenewal fee
13.12.2012Renewal fee patent year 03
29.07.2013Renewal fee patent year 04
28.07.2014Renewal fee patent year 05
24.07.2015Renewal fee patent year 06
20.07.2016Renewal fee patent year 07
19.07.2017Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.07.201203   M06   Fee paid on   13.12.2012
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.07.2010
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
MK21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
MT14.07.2018
IS21.07.2018
PT23.07.2018
BE31.07.2018
[2020/33]
Former [2020/31]HU14.07.2010
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
MK21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
MT14.07.2018
PT23.07.2018
BE31.07.2018
Former [2020/28]HU14.07.2010
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
MT14.07.2018
PT23.07.2018
BE31.07.2018
Former [2020/16]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
MT14.07.2018
PT23.07.2018
BE31.07.2018
Former [2020/08]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
MT14.07.2018
PT23.07.2018
BE31.07.2018
Former [2019/26]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
PT23.07.2018
BE31.07.2018
Former [2019/24]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
PT23.07.2018
BE31.07.2018
Former [2019/19]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IE14.07.2018
LU14.07.2018
PT23.07.2018
Former [2019/17]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
LU14.07.2018
PT23.07.2018
Former [2019/15]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/08]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/03]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2018/52]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/50]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/49]AL21.03.2018
CY21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/47]AL21.03.2018
CY21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/46]AL21.03.2018
CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/40]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/37]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NL21.03.2018
NO21.06.2018
GR22.06.2018
Former [2018/35]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NL21.03.2018
NO21.06.2018
Cited inInternational search[I]WO2007076927  (MERCK PATENT GMBH [DE], et al) [I] 1,4 * page 36 - page 39 *;
 [A]US6086874  (YOSHIDA OSAMU [JP], et al) [A] 1-10 * figures 3,9; examples 1-4; claims 1-11 *;
 [IY]  - VAN ZAANEN H C T ET AL, "Endogenous interleukin 6 production in multiple myeloma patients treated with himeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, (19960901), vol. 98, no. 6, doi:10.1172/JCI118932, ISSN 0021-9738, pages 1441 - 1448, XP008092204 [I] 1,4 * abstract * [Y] 2,3,5-8,10

DOI:   http://dx.doi.org/10.1172/JCI118932
 [Y]  - KOVACS EVA, "Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model.", THESCIENTIFICWORLDJOURNAL, (2006), vol. 6, ISSN 1537-744X, pages 888 - 898, XP008127870 [Y] 2,3,5-8,10 * the whole document *

DOI:   http://dx.doi.org/10.1100/tsw.2006.178
 [X]  - MIMA TORU ET AL, "Clinical value of blocking IL-6 receptor.", CURRENT OPINION IN RHEUMATOLOGY, (200905), vol. 21, no. 3, ISSN 1531-6963, pages 224 - 230, XP008127885 [X] 9 * page 225, column l, paragraph 3 *

DOI:   http://dx.doi.org/10.1097/BOR.0b013e3283295fec
 [T]  - KOVACS EVA, "Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?", LEUKEMIA RESEARCH, (201007), vol. 34, no. 7, ISSN 1873-5835, pages 912 - 916, XP002604659 [T] * the whole document *
 [T]  - GOUGELET ANGÉLIQUE ET AL, "Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody.", PLOS ONE, (2009), vol. 4, no. 11, ISSN 1932-6203, pages 1 - 13, XP002605105 [T] * abstract *

DOI:   http://dx.doi.org/10.1371/journal.pone.0008026
Examination   - ULRIKE KLEIN ET AL, "Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone", ANNALS OF HEMATOLOGY, SPRINGER, BERLIN, DE, (20080731), vol. 88, no. 1, ISSN 1432-0584, pages 67 - 71, XP019655015
    - KOVACS-BENKE EVA, "Additive/Synergistic effects of Interleukin-6 and Interleukin-10 on the proliferation of human myeloma cells", INTERNATIONAL JOURNAL OF HEMATOLOGY RESEARCH, (201510), vol. 1, no. 3, pages 74 - 78
by applicantUS2009022726
 US2009035281
    - YOKOE ET AL., BREAST CANCER, (2000), vol. 7, pages 187 - 190
    - ZHUANG; ADACHI, ANTICANCER RES, (1999), vol. 19, pages 1427 - 1432
    - BARBER ET AL., CLIN SCI, (1991), vol. 96, pages 83 - 87
    - BELLUCO ET AL., ANN SURG ONCOL, (2000), vol. 7, pages 133 - 138
    - HOHEISEL ET AL., CLIN INVEST, (1998), vol. 65, pages 183 - 186
    - HATA ET AL., BLOOD, (1995), vol. 86, pages 1039 - 1945
    - NORDAN; POTTER, SCIENCE, (1986), vol. 233, pages 566 - 569
    - DUVILLARD ET AL., BRIT J HAEMATOL, (1995), vol. 89, pages 243 - 249
    - WIERZBOWSKA ET AL., BRIT J HAEMATOL, (1999), vol. 105, pages 412 - 419
    - NACHBOUR ET AL., ANN HEMATOL, (1991), vol. 62, pages 54 - 58
    - DU VILLARD ET AL., BRIT J HAEMATOL, (1995), vol. 89, pages 243 - 249
    - YEE ET AL., BLOOD, (1989), vol. 74, pages 798 - 804
    - STASI ET AL., EUR J HAEMATOL, (1995), vol. 54, pages 9 - 17
    - SEYMOUR ET AL., AM JMED, (1997), vol. 102, pages 21 - 28
    - KATO ET AL., LEUK LYMPH, (1997), vol. 29, pages 71 - 79
    - GAILLARD ET AL., EUR J IMMUNOL, (1987), vol. 27, pages 332 - 3340
    - PAPADAKI ET AL., ACTA HAEMATOLOGICA, (1997), vol. 97, pages 191 - 195
    - PULKKI ET AL., BRIT J HAEMATOL, (1996), vol. 92, pages 370 - 374
    - LAVABRE-BERTRAND ET AL., BRIT JHAEMATOL, (1995), vol. 91, pages 871 - 877
    - OHTANI ET AL., BRIT J HAEMATOL, (1995), vol. 91, page 116 120
    - MITSUYAMA ET AL., GUT, (1995), vol. 36, pages 45 - 49
    - JABLONSKA, CYTOKINE, (1998), vol. 10, pages 540 - 543
    - KOVACS, BIOMED PHARMACOTHER, (2001), vol. 55, pages 391 - 396
    - MOORE ET AL., ANNU REV IMMUNOL, (2001), vol. 19, pages 683 - 765
    - KRüGER ET AL., BR J CANCER, (1994), vol. 70, pages 1182 - 1185
    - GOTLIEB ET AL., CYTOKINE, (1992), vol. 4, pages 385 - 390
    - DE VITA ET AL., CANCER, (1999), vol. 86, pages 1936 - 1943
    - CHAU ET AL., ANN SURG, (2000), vol. 231, pages 552 - 558
    - DE VITA ET AL., CHEST, (2000), vol. 117, pages 365 - 373
    - WITTKE ET AL., BR J CANCER, vol. 79, pages 1182 - 1184
    - MASOOD ET AL., BLOOD, (1995), vol. 85, pages 3423 - 3430
    - JONES ET AL., BLOOD, (1999), vol. 94, pages 2871 - 2879
    - VOORZANGER ET AL., CANCER RESEARCH, (1996), vol. 56, pages 5499 - 5505
    - KOVACS, LEUKEMIA RESEARCH, (2010), vol. 34, pages 912 - 916
    - LU ET AL., BLOOD, (1995), vol. 85, pages 2521 - 2527
    - OTSUKI ET AL., BRIT JHAEMATOL, (2000), vol. 111, pages 835 - 842
    - OTSUKI ET AL., LEUK LYMPHOMA, (2002), vol. 43, pages 969 - 974
    - HADDAD ET AL., BLOOD, (2001), vol. 97, pages 1590 - 1597
    - ZAANEN ET AL., CLIN INVEST, (1996), vol. 98, pages 1441 - 1448
    - SUZUKI ET AL., EUR JLMMUNOL, (1992), vol. 22, pages 1989 - 1993
    - CAMPO ET AL., CYTOKINE, (2005), vol. 31, pages 368 - 374
    - VOORHEES ET AL., CLIN CANCER RES, (2007), vol. 13, pages 6469 - 6478
    - OLDFIELD ET AL., DRUGS, (2009), vol. 69, pages 609 - 632
    - MIHARA ET AL., INT IMMUNOPHARMACOL, (2005), vol. 5, pages 1731 - 1740
    - TASSONE ET AL., CLIN CANCER RES, (2006), vol. 11, pages 425 - 58
 EP19900109583
 US19970860487
 EP20040792816
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.